| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22025 |
| Drug | Tepotinib |
| Brand | Tepmetko® |
| Indication | For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 22/04/2022 |
| Rapid review completed | 30/05/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tepotinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/07/2022 |
| Pre-submission consultation with Applicant | 13/09/2022 |
| Full submission received from Applicant | 10/01/2023 |
| Preliminary review sent to Applicant | 23/05/2023 |
| NCPE assessment re-commenced | 22/06/2023 |
| Factual accuracy sent to Applicant | 18/10/2023 |
| NCPE assessment re-commenced | 03/11/2023 |
| NCPE assessment completed | 29/11/2023 |
| NCPE assessment outcome | The NCPE recommends that tepotinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
